August 1, 2018 – Charleston, SC, USA – RichSource Stem Cells, Inc. (RichSource), a leader in the business development and distribution of human tissue allograft combination products and membranes, announced today its own brand product line: RICHGEN. With the introduction of this breakthrough line, the industry is no longer limited to single material post-birth, multipotent cellular products. Available throughout the U.S., the RICHGEN product line is backed by an experienced nationwide team of RichSource Area Vice Presidents who can educate, train and provide support to physician practices and networks. Additionally, RichSource’s simplified and more effective treatment protocols helps to optimize practices and patient results.
“We are no longer in the infancy stage of regenerative medicine, limited to using surgery to extract low quality stem cells from patients. Finally, practitioners can now offer their patients non-invasive options. Today, RICHGEN injectables can be thawed in three minutes and used for treatments. This will modernize therapy, avoiding or postponing surgery for most indications. ” — Sara Oracle, CEO & President, RichSource Stem Cells, Inc.
Unrivaled in the marketplace, RICHGEN is the first combination regenerative medicine made of these four key materials: placenta, Wharton’s jelly, amniotic fluid and amnion membrane. RICHGEN provides physicians with injectable undifferentiated pluripotent cells that deliver maximum signaling for healing. Additional amnion membrane, chorion membrane and a combination optic membrane product are available.
The RICHGEN allografts’ bioactive proteins—combined with the extracellular matrix, lamin and Fibronectin—present a functional allograft that is effective in a wide array of applications. These include topical wound healing, rapid response use in orthopedic pathologies, organ system pathologies, pain/inflammation control, scar management by following the inflammatory chemotactic pathways and providing components, immunomodulation, and scaffolding for healthy tissue generation and repair of injured tissue.
RICHGEN is regulated as a human cellular or tissue-based product (HCT/P) under 21 CFR Part 1271 and Section 361 of the Public Health Service Act and AATB, FDA and ISO 13485 guidelines. FDA registered, inspected and cGMP compliant. The RICHGEN brand is distributed by RichSource Stem Cells, Inc.
RichSource Stem Cells, Inc.
Email: [email protected]